The Delaware County Daily Times
The 2015 BIO International Convention is coming to Philadelphia Click here to read story
Anavex Encouraged by Data Showing Sigma-1 Receptor Reduces Tau Dysfunction, a Hallmark of Alzheimer’s Disease
New Report Validates Therapeutic Application of Anavex Compounds in Tau Diseases NEW YORK, NY – May 21, 2015 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (OTCQX: AVXL), a clinical-stage biopharmaceutical company developing drug candidates to treat Alzheimer’s disease, other central nervous system (CNS) diseases, pain, and various types of cancer, is encouraged by…
Anavex Releases Promising Full Preclinical Epilepsy Data at Antiepileptic Drug Trials XIII Conference
Company’s lead Sigma-1 agonist, ANAVEX 2-73 demonstrates robust anti-seizure effects in well established preclinical seizure models NEW YORK, NY – May 18, 2015 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (OTCQX: AVXL), a clinical-stage biopharmaceutical company developing drug candidates to treat Alzheimer’s disease, other central nervous system (CNS) diseases, pain and various types…
Anavex Reports Fiscal Second Quarter 2015 Financial Results
NEW YORK, NY – May 15, 2015 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (OTCQX: AVXL), a clinical-stage biopharmaceutical company developing drug candidates to treat Alzheimer’s disease, other central nervous system (CNS) diseases, pain and various types of cancer, today reported financial results for the three and six months ended March 31, 2015.…
Anavex to Present at 2015 Marcum Conference on May 27th
NEW YORK, NY – May 13, 2015 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (OTCQX: AVXL) today announced that Christopher U. Missling, PhD, President and Chief Executive Officer, will present at the 2015 Marcum Microcap Conference on Wednesday, May 27, 2015 at 3:30 p.m. ET in the Winter Garden room at the Grand…
Sigma-1 receptor regulates Tau phosphorylation and axon extension by shaping p35 turnover via myristic acid
Proceedings of the National Academy of Sciences (May 2015) Shang-Yi A. Tsai, Michael J. Pokrass, Neal R. Klauer, Hiroshi Nohara and Tsung-Ping Su View Paper
Anavex to Present on Sigma-1 Receptors at the World Orphan Drug Congress and to Reveal New Epilepsy Data at Antiepileptic Drug Trials XIII Conference
NEW YORK, NY – April 23, 2015 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (OTCQX: AVXL) today announced that Christopher U. Missling, PhD, President and Chief Executive Officer, will present at the World Orphan Drug Congress on Thursday, April 23, 2015 at 11:10 a.m. ET at The Washington Hilton in Washington, DC. In a…
Anavex Encouraged by New Scientific Data Revealing Positive Role of Sigma-1 Receptors in Brain Injuries
Report Further Validates Therapeutic Application of Proprietary Anavex Compounds in Multiple Neurological Diseases NEW YORK, NY – April 7, 2015 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (OTCQX: AVXL) is encouraged by the findings of a new report in the latest issue of peer-reviewed scientific journal Neuroscience Letters. The study demonstrates for the first time…
Anavex Presents Positive Results for Both ANAVEX 2-73 and ANAVEX 3-71 in Alzheimer’s Models at 2015 AD/PD™ Conference
ANAVEX 2-73 strong reversal of memory impairment in Alzheimer’s disease model ANAVEX 3-71 strong reversal of synaptic loss in Alzheimer’s disease models NEW YORK, NY – March 23, 2015 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (OTCQX: AVXL), a clinical-stage biopharmaceutical company developing drug candidates to treat Alzheimer’s and other central nervous system…
New Data on Two Anavex Alzheimer’s Drugs to be Unveiled at AD/PD 2015
NEW YORK, NY – March 19, 2015 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (OTCQX: AVXL), a clinical-stage biopharmaceutical company developing drug candidates to treat Alzheimer’s and other central nervous system (CNS) diseases, pain and various types of cancer, is pleased to announce the upcoming presentation of new data for two of its…